title: Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors.
abstract: This trial evaluated the effect of gefitinib on the plasma circulating levels of epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMP)-2 and -9 of patients treated on a pediatric Phase I trial. Complete plasma correlative studies were obtained from 16 of the 25 enrolled patients. There was a trend for lower MMP-2 baseline levels in patients with partial response or stable disease. The Ewing sarcoma from the only patient with partial response lacked egfr mutations. Gefitinib did not induce any significant variation in the levels of the assessed parameters, and none of these determinations showed significant predictive or prognostic value.
authors.affiliation: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231-1000, and Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
authors.forename: Antonio
authors.initials: A
authors.lastname: Jimeno
authors.forename: Najat C
authors.initials: NC
authors.lastname: Daw
authors.forename: Maria L
authors.initials: ML
authors.lastname: Amador
authors.forename: George
authors.initials: G
authors.lastname: Cusatis
authors.forename: Peter
authors.initials: P
authors.lastname: Kulesza
authors.forename: Mark
authors.initials: M
authors.lastname: Krailo
authors.forename: Ashish M
authors.initials: AM
authors.lastname: Ingle
authors.forename: Susan M
authors.initials: SM
authors.lastname: Blaney
authors.forename: Peter
authors.initials: P
authors.lastname: Adamson
authors.forename: Manuel
authors.initials: M
authors.lastname: Hidalgo
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood; D002648:Child; D002675:Child, Preschool; D066246:ErbB Receptors / Q000097:blood / Q000187:drug effects*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D007223:Infant; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood / Q000187:drug effects; D020780:Matrix Metalloproteinase 9 / Q000097:blood / Q000187:drug effects; D020782:Matrix Metalloproteinases / Q000097:blood / Q000187:drug effects*; D009369:Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D011799:Quinazolines; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors; D020782:Matrix Metalloproteinases; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D000077156:Gefitinib